Published in Vaccine Weekly, October 1st, 2003
Under this award, DVC plans to develop the manufacturing processes for a safe and efficacious vaccine that will protect against all known forms of botulinum neurotoxins within 5 years. These processes would then be available for transition into pilot lot manufacture of the vaccine prior to phase I...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.